Karyotype in acute myeloblastic leukemia: prognostic significance for bone marrow transplantation in first remission: a European Group for Blood and Marrow Transplantation study. Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT).

The presentation cytogenetic result was correlated with outcome for 999 patients with acute myeloblastic leukemia (AML) having bone marrow transplantation (BMT) in first complete remission (CR1). The karyotype at diagnosis was classified according to the modified Chicago classification. Allogeneic BMT (AlloBMT) was performed in 500 patients and autologous BMT (ABMT) in 499 patients. For both groups, an abnormal chromosome (abn) 5 and/or 7 or a hypodiploid karyotype had a poor outcome, whereas t(15;17), pseudodiploidy, hyperdiploidy and diploidy were associated with a standard prognosis. Abn (16) and t(8;21) were also of standard prognosis for ABMT, but favorable for AlloBMT. When comparing AlloBMT and ABMT in patients with favorable or standard cytogenetics, AlloBMT was of benefit for remission duration and leukemia-free survival (LFS). Patients with an unfavorable karyotype had a similar outcome, regardless of type of BMT. By multivariate analysis, cytogenetics at diagnosis had the strongest prognostic value for relapse, LFS, and survival in AlloBMT. In ABMT, cytogenetics influenced relapse and LFS. We concluded that the karyotype at diagnosis had important prognostic implication in AML grafted in CR1.

[1]  S. Forman.  Stem cell transplantation in acute leukemia , 1998, Current opinion in oncology.

[2]  J. Klein,et al.  Impact of cytogenetic abnormalities on outcome of bone marrow transplants in acute myelogenous leukemia in first remission. , 1995, Bone marrow transplantation.

[3]  M. Slovak,et al.  Trisomy 11: an association with stem/progenitor cell immunophenotype , 1995, British Journal of Haematology.

[4]  E. Estey,et al.  Cytogenetic and clinical correlates in AML patients with abnormalities of chromosome 16. , 1995, Leukemia.

[5]  A. Delannoy,et al.  Karyotype in acute myeloblastic leukemia: prognostic significance in a prospective study assessing bone marrow transplantation in first remission. , 1995, Bone marrow transplantation.

[6]  F. Mandelli,et al.  Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. , 1995, The New England journal of medicine.

[7]  P. Maslak,et al.  Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: impact of leukocytosis, low-dose chemotherapy, PMN/RAR-alpha isoform, and CD13 expression in patients treated with all-trans retinoic acid. , 1994, Blood.

[8]  M. Labopin,et al.  One hundred twenty-five adult patients with primary acute leukemia autografted with marrow purged by mafosfamide: a 10-year single institution experience. , 1994, Blood.

[9]  R. Mayer,et al.  Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. , 1994, The New England journal of medicine.

[10]  E. Thiel,et al.  Correlation of cytogenetic findings with clinical features in 18 patients with inv(3)(q21q26) or t(3;3)(q21;q26). , 1994, Leukemia.

[11]  A. Grañena,et al.  European survey of bone marrow transplantation in acute promyelocytic leukemia (M3). Working Party on Acute Leukemia of the European Cooperative Group for Bone Marrow Transplantation (EMBT). , 1994, Bone marrow transplantation.

[12]  C. Bloomfield,et al.  Long-term survival in acute myelogenous leukemia: a second follow-up of the Fourth International Workshop on Chromosomes in Leukemia. , 1994, Cancer genetics and cytogenetics.

[13]  M. Caligiuri,et al.  Molecular rearrangement of the ALL-1 gene in acute myeloid leukemia without cytogenetic evidence of 11q23 chromosomal translocations. , 1994, Cancer research.

[14]  A. Cork,et al.  Detection of the AML1/ETO fusion transcript in the t(8;21) masked translocation in acute myelogenous leukemia. , 1993, Cancer research.

[15]  M. Tribalto,et al.  Incidence of chromosome abnormalities and clinical significance of karyotype in de novo acute myeloid leukemia. , 1993, Cancer genetics and cytogenetics.

[16]  H. Dombret,et al.  All-transretinoic acid followed by intensive chemotherapy gives a high complete remission rate and may prolong remissions in newly diagnosed acute promyelocytic leukemia: a pilot study on 26 cases. , 1992, Blood.

[17]  C. Marosi,et al.  Prognostic impact of karyotype and immunologic phenotype in 125 adult patients with de novo AML. , 1992, Cancer genetics and cytogenetics.

[18]  M. Labopin,et al.  Autologous bone marrow transplantation for acute myeloblastic leukemia in Europe : further evidence of the role of marrow purging by mafosfamide , 1991 .

[19]  P. Sonneveld,et al.  Autologous bone marrow transplantation in acute myeloid leukemia in first remission: results of a Dutch prospective study. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  A. Rimm,et al.  Graft-versus-leukemia reactions after bone marrow transplantation. , 1990, Blood.

[21]  C. Bloomfield,et al.  The clinical significance of karyotype in acute myelogenous leukemia. , 1989, Cancer genetics and cytogenetics.

[22]  R Storb,et al.  Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. , 1989, Blood.

[23]  T. Stijnen,et al.  Treatment of acute myelogenous leukemia. An EBMT-EORTC retrospective analysis of chemotherapy versus allogeneic or autologous bone marrow transplantation. , 1989, European journal of cancer & clinical oncology.

[24]  Edward J. Lee,et al.  Prognostic impact of cytogenetic abnormalities in patients with de novo acute nonlymphocytic leukemia. , 1989, Blood.

[25]  F. Appelbaum,et al.  Chemotherapy v marrow transplantation for adults with acute nonlymphocytic leukemia: a five-year follow-up , 1988 .

[26]  F. Appelbaum,et al.  Chemotherapy v marrow transplantation for adults with acute nonlymphocytic leukemia: a five-year follow-up. , 1988, Blood.

[27]  E. Gehan,et al.  Cytogenetic pattern in acute myelogenous leukemia: a major reproducible determinant of outcome. , 1988, Leukemia.

[28]  R. Elashoff,et al.  Treatment of Acute Myelogenous Leukemia: A Prospective Controlled Trial of Bone Marrow Transplantation Versus Consolidation Chemotherapy , 1985 .

[29]  R. Storb,et al.  Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. , 1979, The New England journal of medicine.